Syniad’s Gemina Laboratories To Participate In Poster Session At American Association Of Clinical Chemistry Annual Scientific Meeting

June 15, 2023, Vancouver, British Columbia- Syniad Innovations Inc. (“Syniad”) is pleased to announce that Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is attending the American Association of Clinical Chemistry (“AACC”) Annual Scientific Meeting & Clinical Lab Expo running from Sunday, July 23rd, 2023 to Thursday, July 27th, 2023 in Anaheim, California.

Gemina will be participating in the AACC poster session running from 9:30 am to 5:00 pm on Tuesday, July 25th and Wednesday, July 26th, during which we will announce another major milestone achieved with the Gemina Bridge protein immobilization chemistry on the lateral flow assay format.

Attendees at the conference who wish to speak with the Gemina team in person, should come to the Gemina poster between 1:30 pm and 2:30 pm on Tuesday and Wednesday. The e-poster and audio narration will also be available online through the AACC Digital Platform from Tuesday, July 25th, for Digital Pass Select attendees and from Friday, July 28th for in-person attendees.

In parallel with the poster presentation, the poster will also be available on the Gemina Website for non-attendees of AACC.

For more information, please contact:

Investor Relations

Syniad Innovations

investor@syniadinnovations.com

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.